NHS Has Cut Its Drug Spend by 29%
Humira
Category
Humira Biosimilar IBI303 Does Well in Phase 3 Chinese Clinical Trial Led by Tsinghua University School of Medicine
Tsinghua University, School of Medicine and led a study comparing the efficacy and safety of IBI303 and the originator drug adalimumab (Humira®) on ankylosing spondylitis (AS) patients. IBI303 is comparable and its launch by Innovent Biologics, Inc. is expected to...
TNF Inhibitors and Heart Failure—A Recent Concern for Hidradenitis Suppurativa Patients
The TrialSite Network includes many thousands of Hidradenitis Suppurativa patients eager for greater focus and investment, research, and breakthrough therapies for this debilitating disease impacting approximately 3.3 million in the United States. We have recently...
Samsung Bioepis HUMIRA Biosimilar Approved in the U.S. & Will be Available in June 2023 Due to Patent Thicket
Samsung Bioepis Co. Ltd. reports that the U.S. FDA has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult...
First Patient Enrolled in Phase 3 Study Evaluating HUMIRA Biosmilar
Alvotech, whose drug candidate AVT02 is being developed as a biosimilar to adalimumab (Humira, AbbVie), enrolled the first patient in a clinical phase 3 study evaluating the product, the company recently announced in a press release. Adalimumab, a tumor necrosis...
Biosimilars Increase Prices!
A study from last year focusing on cost trends for tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) after the entry of new competition reveals disturbing trends: new biosimilar competition, long assumed to drive down pricing, does not lower drug...
Hidradenitis Suppurativa Patient Website: Does It Live Up to Its Name?
Recently, a TrialSite News reader—a Hidradenitis Suppurativa (HS) patient—brought a website to our attention. Apparently, this individual, who has been struggling with HS, was searching for an HS doctor. She Google-searched the search term “best Hidradenitis...
PharmaWatch: German Boehringer Ingelheim Taking on an American Thorny Thicket
Delaware federal court Judge Richard Lloret recently ordered AbbVie to immediately produce important Humira® documentation to defendant Boehringer Ingelheim (BI) in what is turning out to be a dramatic legal thriller. The stakes are big. Humira® is a $20 billion drug...
AbbVie Closed Another Humira Biosimilar Deal with Pfizer
See The Pharma Letter to learn more about a recent deal where AbbVie licensed biosimilar adalimumab to Pfizer. Under the deal terms, AbbVie will grant Pfizer a non-exclusive license on specified dates to AbbVie’s intellectual property relating to TNF inhibitor Humira...
AbbVie and Abbott Labs Settle with Government to Resolve Claims & Kickback Allegations
Both Abbott Laboratories and AbbVie Inc. will settle with the federal government for allegations that they employed kickbacks and unlawful methods of marketing and promotion to sell more TriCor® subscriptions. The allegations are based on activities between 2006 to...
California Sues AbbVie for Alleged Humira Kickback Scheme
TrialSite News include link to the actual lawsuit. The California Department of Insurance sued AbbVie last month for allegedly orchestrating a wide ranging kickback scheme to illegally boost prescriptions of its best-selling Humira drug. Filed in Alameda County...